US Patent 8354509 Antibodies to human programmed death receptor PD-1

US Patent 12134654 Multispecific molecules and uses thereof

US Patent 12123003 Synthetic RIG-I-like receptor agonists

US Patent 12122834 Anti-PD-1 antibodies

US Patent 12121565 Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies

US Patent 12110330 Compositions of programmed death receptor 1 (PD-1) antibodies and methods of obtaining the compositions thereof

US Patent 12103922 Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer

US Patent 12091681 Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy

US Patent 12091466 Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies

US Patent 12084518 Trispecific binding proteins and methods of use

US Patent 12083112 Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer

US Patent 12077761 Systems and methods for genetic manipulation of

US Patent 12077554 CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer

US Patent 12076375 Treating and preventing

US Patent 12060432 Combination therapies with anti-CD38 antibodies

US Patent 12059474 Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins